Business Description
Prescient Therapeutics Ltd
NAICS : 325412
ISIN : AU000000PTX3
Description
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 43.98 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -26 | |||||
| 3-Year EPS without NRI Growth Rate | -4.6 | |||||
| 3-Year FCF Growth Rate | -14.5 | |||||
| 3-Year Book Growth Rate | -11.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | 71.03 | |||||
| 12-1 Month Momentum % | 281.54 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.08 | |||||
| Quick Ratio | 8.08 | |||||
| Cash Ratio | 6.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.9 | |||||
| Shareholder Yield % | -0.05 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -37.02 | |||||
| ROA % | -33.73 | |||||
| ROIC % | -254.15 | |||||
| ROC (Joel Greenblatt) % | -835.81 | |||||
| ROCE % | -48.92 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.23 | |||||
| Price-to-Tangible-Book | 2.75 | |||||
| EV-to-EBIT | -2.32 | |||||
| EV-to-EBITDA | -2.32 | |||||
| EV-to-FCF | -3.42 | |||||
| Price-to-Net-Current-Asset-Value | 2.75 | |||||
| Price-to-Net-Cash | 2.75 | |||||
| Earnings Yield (Greenblatt) % | -43.06 | |||||
| FCF Yield % | -18.75 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Prescient Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | 0 | ||
| Beta | 0 | ||
| Volatility % | 107.44 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0.003786 | ||
| 20-Day SMA (€) | 0 | ||
| 12-1 Month Momentum % | 281.54 | ||
| 52-Week Range (€) | 0.0285 - 0.154 | ||
| Shares Outstanding (Mil) | 642.58 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Prescient Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Prescient Therapeutics Ltd Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Prescient Therapeutics Ltd Frequently Asked Questions
What is Prescient Therapeutics Ltd(FRA:UDD)'s stock price today?
The current price of FRA:UDD is €0.11. The 52 week high of FRA:UDD is €0.15 and 52 week low is €0.03.
When is next earnings date of Prescient Therapeutics Ltd(FRA:UDD)?
The next earnings date of Prescient Therapeutics Ltd(FRA:UDD) is .
Does Prescient Therapeutics Ltd(FRA:UDD) pay dividends? If so, how much?
Prescient Therapeutics Ltd(FRA:UDD) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers